世界の慢性特発性便秘治療市場2020年-2030年:医薬品クラス別(セロトニン-4 [5-Ht4]受容体アゴニスト、グアニル酸シクラーゼ-Cアゴニスト、下剤、覚醒剤、その他)、投与経路別、流通チャンネル別

◆英語タイトル:Chronic Idiopathic Constipation Treatment Market (Drug Class: Serotonin-4 [5-Ht4] Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants, and Others; Route of Administration: Oral and Rectal; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030(CIC) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 - 2030
◆商品コード:TMR21FB021
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2020年12月15日
◆ページ数:295
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,795 ⇒換算¥660,630見積依頼/購入/質問フォーム
Site Licence(同一拠点内共有可)USD8,795 ⇒換算¥1,002,630見積依頼/購入/質問フォーム
Enterprisewide Licence(複数拠点内共有可)USD11,795 ⇒換算¥1,344,630見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Research社の本市場調査レポートでは、世界の慢性特発性便秘治療市場について調査・分析し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、医薬品クラス別(セロトニン-4 [5-Ht4]受容体アゴニスト、グアニル酸シクラーゼ-Cアゴニスト、下剤、覚醒剤、その他)分析、投与経路別分析、流通チャンネル別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況を掲載しています。
・序論
・仮定/調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界の慢性特発性便秘治療市場規模:医薬品クラス別(セロトニン-4 [5-Ht4]受容体アゴニスト、グアニル酸シクラーゼ-Cアゴニスト、下剤、覚醒剤、その他)
・世界の慢性特発性便秘治療市場規模:投与経路別
・世界の慢性特発性便秘治療市場規模:流通チャンネル別
・世界の慢性特発性便秘治療市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況
【レポートの概要】

Chronic Idiopathic Constipation Treatment Market – Scope of the Report

TMR’s report on the global chronic idiopathic constipation treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global chronic idiopathic constipation treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global chronic idiopathic constipation treatment market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global chronic idiopathic constipation treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global chronic idiopathic constipation treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global chronic idiopathic constipation treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global chronic idiopathic constipation treatment market.

The report delves into the competition landscape of the global chronic idiopathic constipation treatment market. Key players operating in the global chronic idiopathic constipation treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global chronic idiopathic constipation treatment market that have been profiled in this report.

Key Questions Answered in Chronic Idiopathic Constipation Treatment Market Report

What is the scope of growth for product companies in the global chronic idiopathic constipation treatment market?
What will be the Y-o-Y growth of the global chronic idiopathic constipation treatment market between 2020 and 2030?
What is the influence of changing trends in technologies on the global chronic idiopathic constipation treatment market?
Will North America continue to be the most profitable market for chronic idiopathic constipation treatment?
Which factors are anticipated to hamper the global chronic idiopathic constipation treatment market during the forecast period?
Which are the leading companies in the global chronic idiopathic constipation treatment market?
Research Methodology

A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global chronic idiopathic constipation treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global chronic idiopathic constipation treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the chronic idiopathic constipation treatment market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the chronic idiopathic constipation treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global chronic idiopathic constipation treatment market with accuracy. The study also uses the top-down approach to assess the revenues of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global chronic idiopathic constipation treatment more reliably and accurately.

【レポートの目次】

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Chronic Idiopathic Constipation Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Drug Class Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, 2018–2030

5. Key Insights

5.1. Pipeline Analysis

5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

5.3. Diseases Prevalence by Global/Sub-region

5.4. Key Developments

6. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

6.3.1. Serotonin-4 (5-Ht4) Receptor Agonist

6.3.1.1. Prucalopride

6.3.1.2. Others

6.3.2. Guanylate Cyclase-C Agonist

6.3.2.1. Plecanatide

6.3.2.2. Linaclotide

6.3.3. Laxatives

6.3.3.1. Sodium Picosulphate

6.3.3.2. Polycarbophil

6.3.3.3. Others

6.3.4. Stimulants

6.3.4.1. Bisacodyl

6.3.4.2. Senokot

6.3.4.3. Others

6.3.5. Others

6.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class

7. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

7.3.1. Oral

7.3.2. Rectal

7.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration

8. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel

9. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Region

10. North America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

10.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

10.2.1.1. Prucalopride

10.2.1.2. Others

10.2.2. Guanylate Cyclase-C Agonist

10.2.2.1. Plecanatide

10.2.2.2. Linaclotide

10.2.3. Laxatives

10.2.3.1. Sodium Picosulphate

10.2.3.2. Polycarbophil

10.2.3.3. Others

10.2.4. Stimulants

10.2.4.1. Bisacodyl

10.2.4.2. Senokot

10.2.4.3. Others

10.2.5. Others

10.3. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

10.3.1. Oral

10.3.2. Rectal

10.4. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

10.5. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

10.5.1. U.S.

10.5.2. Canada

10.6. North America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

10.6.1. By Drug Class

10.6.2. By Route of Administration

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

11.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

11.2.1.1. Prucalopride

11.2.1.2. Others

11.2.2. Guanylate Cyclase-C Agonist

11.2.2.1. Plecanatide

11.2.2.2. Linaclotide

11.2.3. Laxatives

11.2.3.1. Sodium Picosulphate

11.2.3.2. Polycarbophil

11.2.3.3. Others

11.2.4. Stimulants

11.2.4.1. Bisacodyl

11.2.4.2. Senokot

11.2.4.3. Others

11.2.5. Others

11.3. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

11.3.1. Oral

11.3.2. Rectal

11.4. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

11.5. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

11.6.1. By Drug Class

11.6.2. By Route of Administration

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

12.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

12.2.1.1. Prucalopride

12.2.1.2. Others

12.2.2. Guanylate Cyclase-C Agonist

12.2.2.1. Plecanatide

12.2.2.2. Linaclotide

12.2.3. Laxatives

12.2.3.1. Sodium Picosulphate

12.2.3.2. Polycarbophil

12.2.3.3. Others

12.2.4. Stimulants

12.2.4.1. Bisacodyl

12.2.4.2. Senokot

12.2.4.3. Others

12.2.5. Others

12.3. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

12.3.1. Oral

12.3.2. Rectal

12.4. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

12.6.1. By Drug Class

12.6.2. By Route of Administration

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

13.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

13.2.1.1. Prucalopride

13.2.1.2. Others

13.2.2. Guanylate Cyclase-C Agonist

13.2.2.1. Plecanatide

13.2.2.2. Linaclotide

13.2.3. Laxatives

13.2.3.1. Sodium Picosulphate

13.2.3.2. Polycarbophil

13.2.3.3. Others

13.2.4. Stimulants

13.2.4.1. Bisacodyl

13.2.4.2. Senokot

13.2.4.3. Others

13.2.5. Others

13.3. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

13.3.1. Oral

13.3.2. Rectal

13.4. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

13.6.1. By Drug Class

13.6.2. By Route of Administration

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

14.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

14.2.1.1. Prucalopride

14.2.1.2. Others

14.2.2. Guanylate Cyclase-C Agonist

14.2.2.1. Plecanatide

14.2.2.2. Linaclotide

14.2.3. Laxatives

14.2.3.1. Sodium Picosulphate

14.2.3.2. Polycarbophil

14.2.3.3. Others

14.2.4. Stimulants

14.2.4.1. Bisacodyl

14.2.4.2. Senokot

14.2.4.3. Others

14.2.5. Others

14.3. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

14.3.1. Oral

14.3.2. Rectal

14.4. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

14.5. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

14.6.1. By Drug Class

14.6.2. By Route of Administration

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player – Competition Matrix (By Tier and Size of companies)

15.2. Market Share Analysis/Ranking By Company (2019)

15.3. Company Profiles

15.3.1. Bayer AG

15.3.1.1. Company Overview

15.3.1.2. Company Financials

15.3.1.3. Growth Strategies

15.3.1.4. SWOT Analysis

15.3.2. Allergan

15.3.2.1. Company Overview

15.3.2.2. Company Financials

15.3.2.3. Growth Strategies

15.3.2.4. SWOT Analysis

15.3.3. Bausch Health

15.3.3.1. Company Overview

15.3.3.2. Company Financials

15.3.3.3. Growth Strategies

15.3.3.4. SWOT Analysis

15.3.4. Sanofi

15.3.4.1. Company Overview

15.3.4.2. Company Financials

15.3.4.3. Growth Strategies

15.3.4.4. SWOT Analysis

15.3.5. Takeda Pharmaceutical Company

15.3.5.1. Company Overview

15.3.5.2. Company Financials

15.3.5.3. Growth Strategies

15.3.5.4. SWOT Analysis

15.3.6. SEBELA PHARMACEUTICALS

15.3.6.1. Company Overview

15.3.6.2. Growth Strategies

15.3.6.3. SWOT Analysis

15.3.7. Ironwood Pharmaceuticals, Inc.

15.3.7.1. Company Overview

15.3.7.2. Company Financials

15.3.7.3. Growth Strategies

15.3.7.4. SWOT Analysis

15.3.8. Albireo Pharma, Inc.

15.3.8.1. Company Overview

15.3.8.2. Company Financials

15.3.8.3. Growth Strategies

15.3.8.4. SWOT Analysis

15.3.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt)

15.3.9.1. Company Overview

15.3.9.2. Company Financials

15.3.9.3. Growth Strategies

15.3.9.4. SWOT Analysis

15.3.10. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

15.3.10.1. Company Overview

15.3.10.2. Company Financials

15.3.10.3. Growth Strategies

15.3.10.4. SWOT Analysis

List of Tables

Table 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 03: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 04: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 05: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 06: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 07: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 09: North America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 10: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 11: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 12: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 13: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 14: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 15: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 16: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 17: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 18: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 19: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 20: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 21: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 22: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 23: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 24: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 27: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 28: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 29: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 30: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 31: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 32: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 33: Latin America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 34: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 35: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 36: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 37: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 38: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 39: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 40: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 41: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 42: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 43: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 44: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 45: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 46: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 47: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 48: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Drug Class, 2019

Figure 03: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Route of Administration, 2019

Figure 04: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Distribution Channel, 2019

Figure 05: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Region, 2019

Figure 06: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 07: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Figure 09: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Guanylate Cyclase-C Agonist, 2018–2030

Figure 10: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Laxatives, 2018–2030

Figure 11: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Stimulants, 2018–2030

Figure 12: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Others, 2018–2030

Figure 13: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2019 and 2030

Figure 14: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2020–2030

Figure 15: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Guanylate Cyclase-C Agonist, 2019 and 2030

Figure 16: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Guanylate Cyclase-C Agonist, 2020–2030

Figure 17: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Laxatives, 2019 and 2030

Figure 18: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Laxatives, 2020–2030

Figure 19: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Stimulants, 2019 and 2030

Figure 20: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Stimulants, 2020–2030

Figure 21: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 22: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 23: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Oral, 2018–2030

Figure 24: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Rectal, 2018–2030

Figure 25: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 26: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 27: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 28: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 29: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Online Pharmacies, 2018–2030

Figure 30: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 31: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Region

Figure 32: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 33: North America Chronic Idiopathic Constipation Market Value Share (%), by Country, 2019 and 2030

Figure 34: North America Chronic Idiopathic Constipation Market Attractiveness, by Country, 2020–2030

Figure 35: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 36: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 37: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 38: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 39: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 40: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 41: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 42: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 43: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 44: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 45: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 46: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 47: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 48: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 49: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 50: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 51: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 52: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 53: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 54: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 55: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 56: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 57: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 58: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 59: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 60: Latin America Chronic Idiopathic Constipation Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 61: Latin America Chronic Idiopathic Constipation Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 62: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 63: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 64: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 65: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 66: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 67: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 68: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 69: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 70: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 71: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 72: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 73: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 74: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 75: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 76: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の慢性特発性便秘治療市場2020年-2030年:医薬品クラス別(セロトニン-4 [5-Ht4]受容体アゴニスト、グアニル酸シクラーゼ-Cアゴニスト、下剤、覚醒剤、その他)、投与経路別、流通チャンネル別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆